Pfizer sues India generic drugmaker over cancer drug
Pharmaceutical company Pfizer has accused generic drug maker Aurobindo of infringement, as it attempts to block the roll-out of copies of its blockbuster arthritis drug, Xeljanz.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
15 February 2023 The long-running legal saga between the pharma giant and the NHS as well as generic drug makers has developed further, as Darren Smyth of EIP explains.
21 October 2021 Pfizer is seeking to block a generic version of its cancer drug Ibrance from entering the market until the patent covering the drug expires in May 2036.
22 February 2021 The US Court of Appeals for the Federal Circuit has cancelled claims of a Melanoscan patent covering methods of detecting skin cancer.
15 February 2023 The long-running legal saga between the pharma giant and the NHS as well as generic drug makers has developed further, as Darren Smyth of EIP explains.
21 October 2021 Pfizer is seeking to block a generic version of its cancer drug Ibrance from entering the market until the patent covering the drug expires in May 2036.
22 February 2021 The US Court of Appeals for the Federal Circuit has cancelled claims of a Melanoscan patent covering methods of detecting skin cancer.
15 February 2023 The long-running legal saga between the pharma giant and the NHS as well as generic drug makers has developed further, as Darren Smyth of EIP explains.
21 October 2021 Pfizer is seeking to block a generic version of its cancer drug Ibrance from entering the market until the patent covering the drug expires in May 2036.
22 February 2021 The US Court of Appeals for the Federal Circuit has cancelled claims of a Melanoscan patent covering methods of detecting skin cancer.
